AviadoBio Announces Agreement with Apertura Gene Therapy to License TfR1 CapX™, a Next-Generation Blood-Brain Barrier-Crossing Capsid
Monday 27 April 2026 10:04 pm AviadoBio Ltd. (“AviadoBio”) and Apert[……] Read More
Real‑time stock data, professional analysis, and smart portfolio tools. One platform for all your investing needs.
